Literature DB >> 17625435

Etiologies of chronic liver diseases in Hong Kong.

Konrad Tang-Tat Fung1, James Fung, Ching-Lung Lai, Man-Fung Yuen.   

Abstract

BACKGROUND: In Hong Kong, chronic hepatitis B (CHB) is endemic with a prevalence rate of 8.8%. Data, however, on chronic hepatitis C infection and other nonviral causes of chronic liver disease (CLD) are limited. AIM: To investigate the spectrum of CLDs in Hong Kong.
METHODS: Records of all patients attending the Hepatology Clinic of Queen Mary Hospital, Hong Kong, in 2004 were reviewed to identify those with CLDs and their underlying causes.
RESULTS: A total of 6106 patients were found to have CLD. CHB accounted for 89.4% of the cases, followed by chronic hepatitis C infection (5.1%). Nonviral causes accounted for the remaining 5.5% [alcoholic liver disease (ALD) (1.7%), nonalcoholic fatty liver disease (1.5%), primary biliary cirrhosis (PBC) (1.3%)]. Patients with CHB and Wilson's disease were significantly younger than patients with other causes (P<0.002). More than 90% of patients with autoimmune hepatitis and PBC were women. The prevalence of CHB infection was lower in patients with PBC than the general population. Among patients with ALD, the prevalence rate was higher for chronic hepatitis C but similar for CHB, as compared with the general population.
CONCLUSIONS: Despite universal HBV vaccination since 1988, CHB remains the commonest cause of CLD in Hong Kong. PBC and nonalcoholic fatty liver disease were not rare in the Chinese population, being important causes of nonviral liver disease. The prevalence of chronic viral infection among patients with PBC or ALD confirmed the findings of other published literatures.

Entities:  

Mesh:

Year:  2007        PMID: 17625435     DOI: 10.1097/MEG.0b013e3281ace0b7

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

1.  Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis.

Authors:  Na Zeng; Weijia Duan; Sha Chen; Shanshan Wu; Hong Ma; Xiaojuan Ou; Hong You; Yuanyuan Kong; Jidong Jia
Journal:  Hepatol Int       Date:  2019-09-25       Impact factor: 6.047

2.  Prognostic factors and survival analysis of antimitochondrial antibody-positive primary biliary cirrhosis in Chinese patients.

Authors:  Dan-Tong Zhao; Hui-Yu Liao; Yan-Min Liu; Yan Zhao; Xia Feng; Hui-Ping Yan
Journal:  Dig Dis Sci       Date:  2011-03-16       Impact factor: 3.199

3.  Treatment responses in Asians and Caucasians with chronic hepatitis C infection.

Authors:  Kenneth-K Yan; Marianne Guirgis; Thuy Dinh; Jacob George; Anouk Dev; Alice Lee; Amany Zekry
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

4.  Study of liver cirrhosis over ten consecutive years in Southern China.

Authors:  Xing Wang; Shang-Xiong Lin; Jin Tao; Xiu-Qing Wei; Yuan-Ting Liu; Yu-Ming Chen; Bin Wu
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

5.  Subtle presentation of active primary biliary cirrhosis in chronic hepatitis B: a case report.

Authors:  Asad Javaid; Mugilan Poongkunran; Felicia D Allard; Win Kyaw; Htet Htet Maung; Daryl Lau
Journal:  Gastroenterol Rep (Oxf)       Date:  2016-02-17

6.  Acarbose Use and Liver Injury in Diabetic Patients With Severe Renal Insufficiency and Hepatic Diseases: A Propensity Score-Matched Cohort Study.

Authors:  Chia-Ter Chao; Jui Wang; Jenq-Wen Huang; Kuo-Liong Chien
Journal:  Front Pharmacol       Date:  2018-08-07       Impact factor: 5.810

7.  Protective effect of Phellinus linteus polysaccharide extracts against thioacetamide-induced liver fibrosis in rats: a proteomics analysis.

Authors:  Hualin Wang; Guang Wu; Hyoung Jin Park; Ping Ping Jiang; Wai-Hung Sit; Leo Jld van Griensven; Jennifer Man-Fan Wan
Journal:  Chin Med       Date:  2012-10-18       Impact factor: 5.455

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.